The board of directors pharmaceutical company Allergan plc (NYSE:AGN) approved a dividend of USD0.72 per ordinary share for the first quarter of 2018, the company declared on Friday.
This cash dividend is due on 28 March 2018 to shareholders of record at the close of business as of 28 February 2018.
In addition, the company has scheduled its 2018 Annual General Meeting of Shareholders for 2 May 2018 in Dublin, Ireland. The board has set the close of business on 6 March 2018 as the record date for determining shareholders eligible to vote at the meeting.
Headquartered in Dublin, Ireland, Allergan is focused on developing, manufacturing and commercialising branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.
Coloplast's profit up by 5% in Q1 2018/19
Neurocrine Biosciences achieves higher net income of USD21.1m for 2018
Stellar Biotechnologies incurs Q1 net loss of USD1.41m
Gilead Sciences reports 11% rise in Q1 2019 dividend
Senseonics extends distribution agreement with Roche Diabetes Care
Orexo reports financial results for Q4 2018
AstraZeneca reports completion of divestment of US Synagis rights to Sobi